Stemcell Technologies Inc.

Stemcell Technologies Inc., a foreign-owned subsidiary of Canadian parent Stemcell Tecnologies, supplies specialized biological research materials, cell isolation and purification kits, cell culture media, automated cell separation instruments, and maintenance services to federal health agencies exclusively as a prime contractor operating in full-and-open competition with no small business set-asides. Headquartered in Kent, Washington, the company competes across 404 federal awards with a combined potential value of $18.9 million, all initiated and performed as prime work without subcontractor engagement.

The company's federal footprint concentrates heavily within the National Institutes of Health and related health agencies. The top five NIH-aligned customers account for 51% of recent awards by count, anchored by the National Institute of Allergy and Infectious Diseases (63 awards, $1.5 million combined potential value), the NIAID Delegated Examination and Acquisitions office (45 awards, $1.1 million), the National Heart, Lung, and Blood Institute (40 awards, $518 thousand), the National Institute on Aging (29 awards, $517 thousand), and the NIH Clinical Center (28 awards, $790 thousand). By dollar volume, the ranking reorders sharply: the NIH Office of Logistics and Acquisition Operations dominates at $10.2 million combined potential value across 6 awards, driven by a single-award $10 million Blanket Purchase Agreement awarded December 20, 2023, running through December 31, 2026. This BPA establishes an indefinite delivery vehicle for biological materials, blood products, laboratory supplies, media, and scientific equipment supporting research across multiple NIH institutes. Representative task orders against the BPA include a March 2025 National Heart, Lung, and Blood Institute call for $18,120 in cell purification kits and an August 2024 National Institute of Mental Health call for $19,135.20 in research-grade biological products.

Stemcell Technologies Inc.'s capability portfolio centers on cell isolation and enrichment products sold under proprietary brand families including EasySep kits (human and animal cell isolation), STEMDIFF differentiation and maturation kits, mTESR Plus cell culture media, RoboSep-S automated immunomagnetic cell separators, and STEMVISION automated cell counting and colony-forming-unit readers. Representative prime awards illustrate the mix: a $99,969.58 firm fixed-price purchase order from the Office of Logistics and Acquisition Operations for STEMVISION Automated CFU Reader equipment (awarded September 30, 2026, completion September 2027); a $162,655.20 purchase order from the National Institute on Drug Abuse for RoboSep-S maintenance and repair services running through August 2029; a $99,528 purchase order from the National Institute of Allergy and Infectious Diseases for 160 EasySep Negative Human CD4 Kits supporting HIV immunoregulation research; a $86,359.80 purchase order from the CDC Pittsburgh for laboratory reagents (July 2023 through February 2024); and an $86,487.85 purchase order from the National Institute on Aging for a fully automated RoboSep-S cell separator system (May 2023 award). The company also supplies stand-alone reagent and cell culture materials in smaller orders, frequently sub-$25,000 per award, across NIH institutes pursuing immunology, infectious disease, stem cell research, and translational medicine.

The company holds positions on multiple established federal vehicles anchoring its procurement efficiency. The $10 million NIH BPA (HHSN263201500148B successor) represents the highest-ceiling vehicle. Secondary vehicles include BPA HHSN263200400060978B carrying 57 task orders worth $682 thousand combined potential value, the GSA Federal Supply Schedule GS07F0536T with 14 task orders and $381 thousand combined potential value, and BPA 75N98024A00049 with 2 task orders and $37 thousand combined potential value. These vehicles enable direct task order issuance across NIH centers without individual competitive procurements.

Activity has remained stable but modestly declining in recent years: 14 awards in 2022, 14 in 2023, 10 in 2024, 7 in 2025, and 8 in 2026 through late September. The decline reflects the bounded scope of the $10 million NIH BPA as a single large vehicle alongside many smaller individual purchase orders rather than portfolio collapse. Six awards with ultimate completion dates in the next twenty-four months carry combined potential value of $230 thousand and represent routine recompete exposure. The company served 37 distinct federal customer agencies across the portfolio, though concentration in HHS-NIH work is pronounced—the NIH Office of Logistics and Acquisition Operations and five NIH component institutes and centers represent approximately 75% of combined potential value. Obligated dollars across the portfolio total $8.1 million (43% of potential value), indicating substantial unfunded backlog typical of federal research supply contracting.

The company's NAICS distribution reflects its product and service posture: Testing Laboratories and Services (144 awards), Biological Product Manufacturing except Diagnostics (67 awards), Analytical Laboratory Instrument Manufacturing (60 awards), In-Vitro Diagnostic Substance Manufacturing (20 awards), and Other Scientific and Technical Consulting Services (13 awards). PSC coding aligns with products supplied: Drugs and Biologicals (152 awards), Laboratory Equipment and Supplies (82 awards), Chemicals (31 awards), Drugs and Biologicals Veterinary Use (27 awards), and Maintenance/Repair/Rebuild of Laboratory Equipment (24 awards). The portfolio reflects a specialized supplier profile serving federal research institutions rather than broad federal IT, management services, or defense contractor posture.